Lubiprostone: a novel treatment for chronic constipation.
Article Details
- CitationCopy to clipboard
Lacy BE, Levy LC
Lubiprostone: a novel treatment for chronic constipation.
Clin Interv Aging. 2008;3(2):357-64.
- PubMed ID
- 18686757 [ View in PubMed]
- Abstract
Chronic constipation is highly prevalent, reduces patients' quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue ofprostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Lubiprostone Chloride channel protein 2 Protein Humans YesInducerDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Lubiprostone Carbonyl reductase [NADPH] 1 Protein Humans UnknownSubstrateDetails